Free tool
FAERS Monitor: Lipofen
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021612 or its brand name (Lipofen, Fenofibrate). Reports on generic versions are filed under their own applications.
Reports
35,744
Serious
24,452
68% of reports
Hospitalization
12,434
Death reported
2,830
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue2,198
- diarrhoea2,137
- nausea2,068
- drug ineffective1,825
- headache1,581
- dyspnoea1,552
- off label use1,415
- dizziness1,401
- pain1,395
- fall1,382
- asthenia1,331
- acute kidney injury1,282
- vomiting1,240
- arthralgia1,199
- pruritus1,172
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 264 |
| 2005 | 251 |
| 2006 | 397 |
| 2007 | 300 |
| 2008 | 474 |
| 2009 | 564 |
| 2010 | 677 |
| 2011 | 981 |
| 2012 | 1,105 |
| 2013 | 1,062 |
| 2014 | 1,370 |
| 2015 | 2,187 |
| 2016 | 2,574 |
| 2017 | 2,504 |
| 2018 | 2,793 |
| 2019 | 2,719 |
| 2020 | 2,495 |
| 2021 | 2,265 |
| 2022 | 2,230 |
| 2023 | 2,161 |
| 2024 | 2,070 |
| 2025 | 2,334 |
| 2026 | 1,967 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,018,415 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| acute kidney injurySignal | 1,282 | 5.0 | 4.7 | 4,048 |
| fallSignal | 1,382 | 2.4 | 2.3 | 1,198 |
| astheniaSignal | 1,331 | 2.1 | 2.0 | 763 |
| diarrhoea | 2,137 | 2.0 | 1.9 | 1,018 |
| pruritus | 1,172 | 1.8 | 1.7 | 420 |
| arthralgia | 1,199 | 1.7 | 1.6 | 350 |
| fatigue | 2,198 | 1.7 | 1.6 | 601 |
| dizziness | 1,401 | 1.7 | 1.6 | 370 |
| dyspnoea | 1,552 | 1.6 | 1.5 | 372 |
| vomiting | 1,240 | 1.6 | 1.5 | 249 |
| nausea | 2,068 | 1.5 | 1.5 | 404 |
| headache | 1,581 | 1.5 | 1.4 | 257 |
| pain | 1,395 | 1.3 | 1.3 | 121 |
| off label use | 1,415 | 1.0 | 0.9 | 4 |
| drug ineffective | 1,825 | 0.8 | 0.8 | 82 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.